Nov 01, 2018
Tocagen to Report Third Quarter 2018 Financial Results on Thursday, November 8
Oct 02, 2018
Tocagen Provides Update on European Regulatory Path for Toca 511 & Toca FC
Sep 27, 2018
Tocagen to Participate in Four Investor Conferences in October
Sep 24, 2018
Tocagen Appoints Mohamed Ladha as Vice President to Establish Commercial Organization
Sep 19, 2018
Tocagen Announces Early Completion of Enrollment in Toca 5 Pivotal Phase 3 Brain Cancer Trial
Aug 28, 2018
Tocagen to Participate in Two Investor Conferences Next Week
Aug 23, 2018
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis
Aug 07, 2018
Tocagen Reports Second Quarter 2018 Financial and Business Results
Aug 01, 2018
Tocagen to Report Second Quarter 2018 Financial Results on Tuesday, August 7
Jul 09, 2018
Tocagen Closes Previously Announced License Agreement with ApolloBio to Develop and Commercialize Toca 511 & Toca FC in Greater China
May 14, 2018
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
May 03, 2018
Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 10
Apr 19, 2018
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
Apr 17, 2018
Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences
Apr 16, 2018
Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mar 15, 2018
Tocagen to Present Preliminary Toca 6 Phase 1 Data and Immune Profiling Data at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mar 13, 2018
Tocagen to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium 2018
Mar 08, 2018
Tocagen Reports Fourth Quarter and Full Year 2017 Financial and Business Results
Mar 07, 2018
Tocagen Receives European Medicines Agency Orphan Medicinal Product Designation for Toca 511 & Toca FC for the Treatment of Glioma
Mar 01, 2018
Tocagen to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress on Thursday, March 8